The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression
Depression, Major Depressive Disorder, Unipolar Depression
About this trial
This is an interventional treatment trial for Depression focused on measuring depression, serotonin, norepinephrine, SSRI, Wellbutrin, bupropion, executive function, residual symptoms
Eligibility Criteria
Inclusion Criteria: Depression SSRI-treated Exclusion Criteria: Bipolar disorder Serotonin-norepinephrine reuptake inhibitor (SNRI) or bupropion treatment Treatment-resistant depression Seizure disorder Bulimia or anorexia nervosa Pregnancy
Sites / Locations
- McLean Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Wellbutrin first, then Placebo
Placebo first, then Wellbutrin
Subjects randomly assigned to the Wellbutrin then Placebo group will receive 100mg BID of Wellbutrin at the first visit following intake (Week 0).Subjects will be increased to 150mg Wellbutrin BID at Week 1 unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of bupropion qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on Wellbutrin 100mg BID. At Week 4, subjects will cross-over to placebo and will continue to take placebo until Week 8.
Subjects randomly assigned to the Placebo then Wellbutrin group will receive placebo until Week 4 when they will cross-over to active drug. At Week 4, subjects will be assigned 100mg Wellbutrin BID. At Week 5, Subjects will be increased to 150mg Wellbutrin BID unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of Wellbutrin qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on bupropion 100mg BID. Subject will continue on the assigned dosage until Week 8 of study.